Clinical studies of Norpace. Summarizing remarks.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D001281:Atrial Fibrillation / Q000188:drug therapy; D001282:Atrial Flutter / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004206:Disopyramide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005080:Exercise Test; D005260:Female; D006327:Heart Block / Q000188:drug therapy; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011725:Pyridines / Q000627:therapeutic use*; D011802:Quinidine / Q000009:adverse effects / Q000627:therapeutic use; D012256:Riboflavin
D000889:Anti-Arrhythmia Agents; D010919:Placebos; D011725:Pyridines; D004206:Disopyramide; D011802:Quinidine; D012256:Riboflavin